Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

GALNT2 suppresses malignant phenotypes through IGF-1 receptor and predicts favorable prognosis in neuroblastoma.

Oncotarget - 15 Dec 2014

Ho Wan-Ling, Chou Chih-Hsing, Jeng Yung-Ming, Lu Meng-Yao, Yang Yung-Li, Jou Shiann-Tarng, Lin Dong-Tsamn, Chang Hsiu-Hao, Lin Kai-Hsin, Hsu Wen-Ming, Huang Min-Chuan

Abstract excerpt

Aberrant expression of the simple mucin-type carbohydrate antigens such as Tn antigen is associated with malignant transformation and cancer progression. N-acetylgalactosaminyltransferase 2 (GALNT2), one of the enzymes that mediate the initial step of mucin-type O-glycosylation, is responsible for forming Tn antigen. GALNT2 is expressed differentially in nervous tissues during mouse embryogenesis; however, the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fluorescent Antibody Technique
Share to Gene Knockdown Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heterografts

Share to Mice, Nude

Share to N-Acetylgalactosaminyltransferases

Share to Neuroblastoma

Share to Polypeptide N-acetylgalactosaminyltransferase

Share to Receptor, IGF Type 1

Source

Open in PubMed Open full text

Identifiers

PMID: 25362349
DOI: 10.18632/oncotarget.2627
PMCID: PMC4322969

Genes

GALNT2
MYCN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

GALNT2 suppresses malignant phenotypes through IGF-1 receptor and predicts favorable prognosis in neuroblastoma.PMID 25362349Read ↗

Protein glycosylation in cancers and its potential therapeutic applications in neuroblastomaSemantic proximity Read ↗

GALNT1 Enhances Malignant Phenotype of Gastric Cancer via Modulating CD44 Glycosylation to Activate the Wnt/β-catenin Signaling Pathway.Semantic proximity Read ↗

GALNT2 sustains glioma stem cells by promoting CD44 expressionSemantic proximity Read ↗

β-1,4-Galactosyltransferase III enhances invasive phenotypes via β1-integrin and predicts poor prognosis in neuroblastoma.Semantic proximity Read ↗

GDP-mannose 4,6-Dehydratase is a Key Driver of MYCN-amplified Neuroblastoma Core Fucosylation and TumorigenesisSemantic proximity Read ↗

GALNT9 Gene Expression Is a Prognostic Marker in Neuroblastoma PatientsSemantic proximity Read ↗

Aberrant N-glycosylation in cancer: MGAT5 and β1,6-GlcNAc branched N-glycans as critical regulators of tumor development and progression.Semantic proximity Read ↗

B4GALNT3 Expression Predicts a Favorable Prognosis and Suppresses Cell Migration and Invasion via β1 Integrin Signaling in NeuroblastomaSemantic proximity Read ↗

GD2 Expression in Medulloblastoma and Neuroblastoma for Personalized Immunotherapy: A Matter of SubtypeSemantic proximity Read ↗

B4GALNT1 induces angiogenesis, anchorage independence growth and motility, and promotes tumorigenesis in melanoma by induction of ganglioside GM2/GD2Semantic proximity Read ↗

GALNT14: An Emerging Marker Capable of Predicting Therapeutic Outcomes in Multiple Cancers.Semantic proximity Read ↗

N‐acetylgalactosaminyltransferase GALNT6 is a potential therapeutic target of clear cell renal cell carcinoma progressionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.